Shares of Viela Bio skyrocketed more than 52% in premarket trading after Ireland’s Horizon Therapeutics announced it was acquiring the company in a $3.05 billion deal that is aimed at expanding that company’s rare disease pipeline and boosting its growth strategy. In its announcement on February 01st, Horizon noted that Maryland’s Viela’s Uplizna, which was approved in June for adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-AQP4 antibody positive, will complement Horizon’s own Tepezza, which was approved in January 2020 for the treatment of Thyroid Eye Diseases, a progressive autoimmune disorder. Uplizna is the first and only FDA-approved B-cell-depleting humanized monoclonal antibody for the treatment of NMOSD, a rare, severe, autoimmune disease that attacks the optic nerve, spinal cord and brain stem. The disease leads to loss of vision and paralysis, in adults who are anti-aquaporin-4 (AQP4) antibody positive.
For further information see BioSpace (https://www.biospace.com/article/horizon-therapeutics-snaps-up-viela-bio-in-3-05-billion-deal/?utm_campaign=GenePool&utm_medium=email&_hsmi=109018868&_hsenc=p2ANqtz–jDn_WCZ1dcz1eISbnrJo7GzT8-VefLeHD4vCMBwRvcPbDyVlz6U7kKNF7BGwE0Imyddx_FCogVn6RO0L0spb2Qnm_jA&utm_content=109018868&utm_source=hs_email)